- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05223062
Medication Adherence in Psoriatic Arthritis
August 26, 2022 updated by: Bezmialem Vakif University
Self-Reported Medication Adherence in Patients With Psoriatic Arthritis: Influence of Illness Perception and Medication Beliefs
Psoriatic arthritis (PsA) is a chronic multisystemic disease requiring ordinary doctor visits and an adherence to medication.
Evaluating the parameters affecting the medication adherence is essential for the efficacy of the treatment.
To our knowledge no study has ever evaluated the factors affecting the medication adherence in patients with PsA so far.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Other: Disease activity in psoriatic arthritis (DAPSA)
- Other: Compliance-Questionnaire-Rheumatology (CQR)
- Other: The Brief Illness Perception Questionnaire (BIPQ)
- Other: The Beliefs About Medicines Questionnaire (BMQ)
- Other: Hospital Anxiety and Depression Scale (HADS)
- Other: The Psoriatic Arthritis Quality of Life (PsAQoL)
Detailed Description
Psoriatic arthritis (PsA) is a multisystemic disease requiring ordinary doctor visits and an adherence to medication.
Due to its chronic nature treatment regimens lasts for the lifetime and that may affect the efficacy of the treatment.
Although treatment with drugs is a biological intervention, medication adherence and eliminating the factors affecting it seems essential for treatment efficacy.
To our knowledge no study has ever evaluated the factors affecting the medication adherence in patients with PsA so far.
Our aim in this study is to evaluate the factors affecting the medication adherence in patients with PsA.
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Fatih
-
Istanbul, Fatih, Turkey, 34093
- Bezmialem Vakif University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with psoriatic arthritis having medication for at least 6 months
Description
Inclusion Criteria:
- Diagnosed with PsA according to CASPAR criteria
- Administering PsA medication for at least 6 moths
- Aged ≥18
Exclusion Criteria:
- Not having enough cognitive functions to understand and answer the questionnaires
- Having a psychiatric disorder
- Having a severe comorbidity (e.g. malignancy, stroke)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Psoriatic arthritis
Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
|
DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level.
The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as "low" adherers (taking <80% of their medication correctly).
The four point Likert answering scale ranges from; "Definitely don't agree" (scored 1) to "Definitely agree" (scored 4) with lower scores indicating lower levels of adherence.
Total score is between 0 and 100.
The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior.
Each item is scored between 0 and 10.
Maximum total score is 80.
Higher scores represents that the patient has a concerned perception of illness.
The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines.
The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general.
It has a total of 18 questions scored with a 5-point Likert scale.
Higher scores represent more powerful beliefs.
Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing.
The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life.
It is a self-administered, 20-item questionnaire that takes about three minutes to complete.
The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life.
Total score is between 0 and 20.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease activity in psoriatic arthritis (DAPSA)
Time Frame: 1 day
|
The score of Disease activity in psoriatic arthritis (DAPSA) provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
Higher scores represent a worse outcome.
|
1 day
|
|
Compliance-Questionnaire-Rheumatology (CQR)
Time Frame: 1 day
|
The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as "low" adherers (taking <80% of their medication correctly).
The four point Likert answering scale ranges from; "Definitely don't agree" (scored 1) to "Definitely agree" (scored 4) with lower scores indicating lower levels of adherence.
Total score is between 0 and 100.
|
1 day
|
|
The Brief Illness Perception Questionnaire (BIPQ)
Time Frame: 1 day
|
The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior.
Each item is scored between 0 and 10.
Maximum total score is 80.
Higher scores represents that the patient has a concerned perception of illness.
|
1 day
|
|
The Beliefs About Medicines Questionnaire (BMQ)
Time Frame: 1 day
|
he Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines.
The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general.
It has a total of 18 questions scored with a 5-point Likert scale.
Higher scores represent more powerful beliefs.
Total score ranges from 4 to 20
|
1 day
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 1 day
|
Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing.
The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
|
1 day
|
|
The Psoriatic Arthritis Quality of Life (PsAQoL)
Time Frame: 1 day
|
The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life.
It is a self-administered, 20-item questionnaire that takes about three minutes to complete.
The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life.
Total score is between 0 and 20.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hromadkova L, Soukup T, Vlcek J. Quality of life and drug compliance: their interrelationship in rheumatic patients. J Eval Clin Pract. 2015 Oct;21(5):919-24. doi: 10.1111/jep.12399. Epub 2015 Jun 17.
- Tolu S, Rezvani A, Karacan I, Bugdayci D, Kucuk HC, Bucak OF, Aydin T. Self-Reported Medication Adherence in Patients With Ankylosing Spondylitis: The Role of Illness Perception and Medication Beliefs. Arch Rheumatol. 2020 Feb 7;35(4):495-505. doi: 10.46497/ArchRheumatol.2020.7732. eCollection 2020 Dec.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2022
Primary Completion (Actual)
August 15, 2022
Study Completion (Actual)
August 15, 2022
Study Registration Dates
First Submitted
January 23, 2022
First Submitted That Met QC Criteria
January 23, 2022
First Posted (Actual)
February 3, 2022
Study Record Updates
Last Update Posted (Actual)
August 29, 2022
Last Update Submitted That Met QC Criteria
August 26, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021/263
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriatic Arthritis
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, France, Greece, Italy, United Kingdom, Austria, Germany, Netherlands, Lithuania, Romania, South Africa, Portugal, Belgium, Turkey (Türkiye), Poland
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Dr. Schär AG / SPAASST Gaetano Pini-CTOCompleted
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Medical College of WisconsinNot yet recruitingPsoriatic Arthritis (PsA)United States
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Poland, Spain, South Korea
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Australia, Belgium, Canada, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom, Argentina, Brazil, Denmark, P... and more
-
Chao JiEnrolling by invitationSubclinical Psoriatic ArthritisChina
-
Sun Pharmaceutical Industries LimitedCompleted
Clinical Trials on Disease activity in psoriatic arthritis (DAPSA)
-
Bezmialem Vakif UniversityCompleted
-
Kutahya Health Sciences UniversityCompletedChronic Pain | Juvenile Idiopathic ArthritisTurkey
-
Sabine DieperinkUniversity of Copenhagen; University of Aarhus; Statens Serum InstitutCompletedRheumatoid Arthritis | Staphylococcus Aureus Bacteremia
-
Glostrup University Hospital, CopenhagenTerminatedSPONDYLOARTHRITISDenmark
-
University Rovira i VirgiliCompleted